529 related articles for article (PubMed ID: 18258423)
1. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial.
Tashkin DP; Littner M; Andrews CP; Tomlinson L; Rinehart M; Denis-Mize K
Respir Med; 2008 Apr; 102(4):479-87. PubMed ID: 18258423
[TBL] [Abstract][Full Text] [Related]
2. Nebulized formoterol provides added benefits to tiotropium treatment in chronic obstructive pulmonary disease.
Tashkin DP; Hanania NA; McGinty J; Denis-Mize K; Chaudry I
Adv Ther; 2009 Nov; 26(11):1024-34. PubMed ID: 19953349
[TBL] [Abstract][Full Text] [Related]
3. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial.
Hanania NA; Boota A; Kerwin E; Tomlinson L; Denis-Mize K
Drugs; 2009 Jun; 69(9):1205-16. PubMed ID: 19537837
[TBL] [Abstract][Full Text] [Related]
5. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD.
Tashkin DP; Pearle J; Iezzoni D; Varghese ST
COPD; 2009 Feb; 6(1):17-25. PubMed ID: 19229704
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study.
Buhl R; Gessner C; Schuermann W; Foerster K; Sieder C; Hiltl S; Korn S
Thorax; 2015 Apr; 70(4):311-9. PubMed ID: 25677679
[TBL] [Abstract][Full Text] [Related]
7. Tiotropium administered by a pressurized metered dose inhaler (pMDI) and spacer produces a similar bronchodilator response as that administered by a Rotahaler in adult subjects with stable moderate-to-severe COPD.
Brashier B; Dhembare P; Jantikar A; Mahadik P; Gokhale P; Gogtay JA; Salvi SS
Respir Med; 2007 Dec; 101(12):2464-71. PubMed ID: 17719763
[TBL] [Abstract][Full Text] [Related]
8. Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD.
Tashkin DP; Donohue JF; Mahler DA; Huang H; Goodwin E; Schaefer K; Hanrahan JP; Andrews WT
Respir Med; 2009 Apr; 103(4):516-24. PubMed ID: 19208459
[TBL] [Abstract][Full Text] [Related]
9. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium.
Donohue JF; Fogarty C; Lötvall J; Mahler DA; Worth H; Yorgancioglu A; Iqbal A; Swales J; Owen R; Higgins M; Kramer B;
Am J Respir Crit Care Med; 2010 Jul; 182(2):155-62. PubMed ID: 20463178
[TBL] [Abstract][Full Text] [Related]
10. Cardiac safety profile of nebulized formoterol in adults with COPD: a 12-week, multicenter, randomized, double- blind, double-dummy, placebo- and active-controlled trial.
Nelson HS; Gross NJ; Levine B; Kerwin EM; Rinehart M; Denis-Mize K;
Clin Ther; 2007 Oct; 29(10):2167-78. PubMed ID: 18042473
[TBL] [Abstract][Full Text] [Related]
11. Bronchodilator efficacy of tiotropium-formoterol via single pressurized meter dose inhaler (pMDI) versus tiotropium alone in COPD.
Salvi S; Brashier B; Gothi D; Karkhanis V; Madas S; Gogtay J; Joshi J
Pulm Pharmacol Ther; 2014 Feb; 27(1):90-5. PubMed ID: 23752057
[TBL] [Abstract][Full Text] [Related]
12. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study.
Vogelmeier C; Kardos P; Harari S; Gans SJ; Stenglein S; Thirlwell J
Respir Med; 2008 Nov; 102(11):1511-20. PubMed ID: 18804362
[TBL] [Abstract][Full Text] [Related]
13. Short-term effects of inhalative tiotropium/formoterol/budenoside versus tiotropium/formoterol in patients with newly diagnosed chronic obstructive pulmonary disease requiring surgery for lung cancer: a prospective randomized trial.
Bölükbas S; Eberlein M; Eckhoff J; Schirren J
Eur J Cardiothorac Surg; 2011 Jun; 39(6):995-1000. PubMed ID: 20970351
[TBL] [Abstract][Full Text] [Related]
14. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD.
van Noord JA; Aumann JL; Janssens E; Smeets JJ; Verhaert J; Disse B; Mueller A; Cornelissen PJ
Eur Respir J; 2005 Aug; 26(2):214-22. PubMed ID: 16055868
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease.
Welte T; Miravitlles M; Hernandez P; Eriksson G; Peterson S; Polanowski T; Kessler R
Am J Respir Crit Care Med; 2009 Oct; 180(8):741-50. PubMed ID: 19644045
[TBL] [Abstract][Full Text] [Related]
16. Effects of tiotropium and formoterol on dynamic hyperinflation and exercise endurance in COPD.
Berton DC; Reis M; Siqueira AC; Barroco AC; Takara LS; Bravo DM; Andreoni S; Neder JA
Respir Med; 2010 Sep; 104(9):1288-96. PubMed ID: 20580216
[TBL] [Abstract][Full Text] [Related]
17. Combined treatment with formoterol and tiotropium is more efficacious than treatment with tiotropium alone in patients with chronic obstructive pulmonary disease, regardless of smoking status, inhaled corticosteroid use, baseline severity, or gender.
Tashkin DP; Varghese ST
Pulm Pharmacol Ther; 2011 Feb; 24(1):147-52. PubMed ID: 20659577
[TBL] [Abstract][Full Text] [Related]
18. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.
Keam SJ; Keating GM
Treat Respir Med; 2004; 3(4):247-68. PubMed ID: 15350163
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of formoterol fumarate delivered by nebulization to COPD patients.
Gross NJ; Nelson HS; Lapidus RJ; Dunn L; Lynn L; Rinehart M; Denis-Mize K;
Respir Med; 2008 Feb; 102(2):189-97. PubMed ID: 18363201
[TBL] [Abstract][Full Text] [Related]
20. Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use.
Decramer M; Dahl R; Kornmann O; Korn S; Lawrence D; McBryan D
Respir Med; 2013 Feb; 107(2):223-32. PubMed ID: 23219347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
